OPHTHALMOLOGY, vol.120, no.4, pp.777-787, 2013 (SCI-Expanded)
Purpose: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.